Genotype-Phenotype Correlations and Sex Differences in ZC4H2-Associated Rare Disorder - 07/08/24
, Kristen Sportiello, BS a, Shreya Mandalapu, BA b, Ashlie Nguyen, PsyD c, Ryan Carrier, MD d, Carolyn Dickinson, NP d, Alex Paciorkowski, MD d, David Bearden, MD dAbstract |
Background |
ZC4H2-associated rare disorder (ZARD) is caused by pathogenic variations in the ZC4H2 gene on the X chromosome. This gene codes for a zinc finger protein involved in neural development. ZARD is characterized by highly variable symptoms, potentially influenced by the sex of the individual.
Methods |
The ZC4H2-Associated Rare Disorder Natural History Study is a prospective natural history study conducted among individuals with ZARD that consists of standardized interviews, developmental assessments, and neurological examinations conducted every six months for two years. In this article, we present data from baseline visits with 40 participants, the largest ZARD cohort studied thus far, focusing on genotype-phenotype correlations and sex differences. Fisher exact, maximum likelihood χ2, and Mann-Whitney tests were utilized.
Results |
Males tended to have maternally inherited ZC4H2 pathogenic variations, whereas females tended to have de novo variations (P < 0.001). Female participants were more likely to have contractures at birth (P < 0.01), arthrogryposis multiplex congenita (P < 0.001), spasticity on examination (P < 0.1), and lower limb muscle atrophy (P < 0.05). Male participants were more likely to have seizures (P < 0.1), intermittent pain (P < 0.01), severe vision impairment (P < 0.05), dysphagia for solids (P < 0.01), and generalized muscle atrophy (P < 0.05).
Conclusions |
Our study suggests there is significant overlap in severity and range of symptoms between males and females, although several symptoms are more common in one sex than the other. Further analysis is needed to better understand how pathogenic variation type affects phenotype.
Le texte complet de cet article est disponible en PDF.Keywords : ZC4H2, ZARD, Arthrogryposis, Genetic disorder, Natural history
Plan
| Contact: For more information on enrolling in this natural history study, please e-mail ZARD_study@urmc.rochester.edu. |
|
| Ethical statement: This study was approved by the Institutional Review Board of the University of Rochester (approved on 12/12/2022; reference number 7737). All procedures complied with relevant laws and institutional guidelines. Verbal and written informed consent was required from the parents (LARs) of all participants to enroll in the study. |
|
| Source of funding: The project described in this publication was supported by the University of Rochester CTSA award number UL1 TR002001 from the National Center for Advancing Translational Sciences of the National Institutes of Health. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. The funding source did not have any involvement in the design, data collection, data analysis, or any other procedures of this research. |
Vol 158
P. 100-112 - septembre 2024 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
